|
1
|
Saha SK, Zhu AX, Fuchs CS and Brooks GA:
Forty-Year trends in cholangiocarcinoma incidence in the U.S.:
Intrahepatic disease on the rise. Oncologist. 21:594–599. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kongpetch S, Jusakul A, Ong CK, Lim WK,
Rozen SG, Tan P and The BT: Pathogenesis of cholangiocarcinoma:
From genetics to signalling pathways. Best Pract Res Clin
Gastroenterol. 29:233–244. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Razumilava N and Gores GJ:
Cholangiocarcinoma. Lancet. 383:2168–2179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Valle JW, Lamarca A, Goyal L, Barriuso J
and Zhu AX: New horizons for precision medicine in biliary tract
cancers. Cancer Discov. 7:943–962. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ikeno Y, Seo S, Iwaisako K, Yoh T,
Nakamoto Y, Fuji H, Taura K, Okajima H, Kaido T, Sakaguchi S and
Uemoto S: Preoperative metabolic tumor volume of intrahepatic
cholangiocarcinoma measured by 18F-FDG-PET is associated
with the KRAS mutation status and prognosis. J Transl Med.
16:952018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hill MA, Alexander WB, Guo B, Kato Y,
Patra K, ODell MR, McCall MN, Whitney-Miller CL, Bardeesy N and
Hezel AF: Kras and Tp53 Mutations cause cholangiocyte- and
hepatocyte-derived cholangiocarcinoma. Cancer Res. 78:4445–4451.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mahipal A, Kommalapati A, Tella SH, Lim A
and Kim R: Novel targeted treatment options for advanced
cholangiocarcinoma. Expert Opin Invest Drugs. 27:709–720. 2018.
View Article : Google Scholar
|
|
8
|
Qiao P, Li G, Bi W, Yang L, Yao L and Wu
D: microRNA-34a inhibits epithelial mesenchymal transition in human
cholangiocarcinoma by targeting Smad4 through transforming growth
factor-beta/Smad pathway. BMC Cancer. 15:4692015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chan-On W, Nairismagi ML, Ong CK, Lim WK,
Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL,
et al: Exome sequencing identifies distinct mutational patterns in
liver fluke-related and non-infection-related bile duct cancers.
Nat Genet. 45:1474–1478. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Andersen JB, Spee B, Blechacz BR, Avital
I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts
LR, et al: Genomic and genetic characterization of
cholangiocarcinoma identifies therapeutic targets for tyrosine
kinase inhibitors. Gastroenterology. 142:1021–1031.e15. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jusakul A, Cutcutache I, Yong CH, Lim JQ,
Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, et
al: Whole-Genome and epigenomic landscapes of etiologically
distinct subtypes of cholangiocarcinoma. Cancer Discov.
7:1116–1135. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zou S, Li J, Zhou H, Frech C, Jiang X, Chu
JS, Zhao X, Li Y, Li Q, Wang H, et al: Mutational landscape of
intrahepatic cholangiocarcinoma. Nat Commun. 5:56962014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo YC, Bao YH, Ma M and Yang WC:
Identification of key candidate genes and pathways in colorectal
cancer by integrated bioinformatical analysis. Int J Mol Sci.
18(Pii): E7222017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fu Q, Yang F, Zhao J, Yang X, Xiang T,
Huai G, Zhang J, Wei L, Deng S and Yang H: Bioinformatical
identification of key pathways and genes in human hepatocellular
carcinoma after CSN5 depletion. Cell Signal. 49:79–86. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang DW, Sherman BT, Tan Q, Collins JR,
Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki
RA: The DAVID gene functional classification tool: A novel
biological module-centric algorithm to functionally analyze large
gene lists. Genome Biol. 8:R1832007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smoot ME, Ono K, Ruscheinski J, Wang PL
and Ideker T: Cytoscape 2.8: New features for data integration and
network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45(D1): D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bader GD and Hogue CW: An automated method
for finding molecular complexes in large protein interaction
networks. BMC Bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tripathi S, Pohl MO, Zhou Y,
Rodriguez-Frandsen A, Wang G, Stein DA, Moulton HM, DeJesus P, Che
J, Mulder LC, et al: Meta- and orthogonal integration of influenza
“OMICs” data defines a role for UBR4 in Virus budding. Cell Host
Microbe. 18:723–735. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang K, Yu J, Yu XL, Han ZY, Cheng ZG,
Liu FY and Liang P: Clinical and survival outcomes of percutaneous
microwave ablation for intrahepatic cholangiocarcinoma. Int J
Hyperthermia. 34:292–297. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rizvi S, Khan SA, Hallemeier CL, Kelley RK
and Gores GJ: Cholangiocarcinoma - evolving concepts and
therapeutic strategies. Nat Rev Clin Oncol. 15:95–111. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bagante F, Gamblin TC and Pawlik TM:
Cholangiocarcinoma risk factors and the potential role of aspirin.
Hepatology. 64:708–710. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rizvi S and Gores GJ: Pathogenesis,
diagnosis, and management of cholangiocarcinoma. Gastroenterology.
145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakamura H, Arai Y, Totoki Y, Shirota T,
Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, et
al: Genomic spectra of biliary tract cancer. Nat Genet.
47:1003–1010. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tanjak P, Thiantanawat A, Watcharasit P
and Satayavivad J: Genistein reduces the activation of AKT and
EGFR, and the production of IL6 in cholangiocarcinoma cells
involving estrogen and estrogen receptors. Int J Oncol. 53:177–188.
2018.PubMed/NCBI
|
|
29
|
Cheon YK, Cho YD, Moon JH, Jang JY, Kim
YS, Kim YS, Lee MS, Lee JS and Shim CS: Diagnostic utility of
interleukin-6 (IL-6) for primary bile duct cancer and changes in
serum IL-6 levels following photodynamic therapy. Am J
Gastroenterol. 102:2164–2170. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Meng F, Yamagiwa Y, Ueno Y and Patel T:
Over-expression of interleukin-6 enhances cell survival and
transformed cell growth in human malignant cholangiocytes. J
Hepatol. 44:1055–1065. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sandanayake NS, Sinclair J, Andreola F,
Chapman MH, Xue A, Webster GJ, Clarkson A, Gill A, Norton ID, Smith
RC, et al: A combination of serum leucine-rich alpha-2-glycoprotein
1, CA19-9 and interleukin-6 differentiate biliary tract cancer from
benign biliary strictures. Br J Cancer. 105:1370–1378. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stine ZE, Walton ZE, Altman BJ, Hsieh AL
and Dang CV: MYC, metabolism, and cancer. Cancer Discov.
5:1024–1039. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Boulter L, Guest RV, Kendall TJ, Wilson
DH, Wojtacha D, Robson AJ, Ridgway RA, Samuel K, Van Rooijen N,
Barry ST, et al: WNT signaling drives cholangiocarcinoma growth and
can be pharmacologically inhibited. J Clin Invest. 125:1269–1285.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang H, Li TW, Peng J, Tang X, Ko KS, Xia
M and Aller MA: A mouse model of cholestasis-associated
cholangiocarcinoma and transcription factors involved in
progression. Gastroenterology. 141:378–388, 388.e1-e4. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang H, Liu T, Wang J, Li TW, Fan W, Peng
H, Krishnan A, Gores GJ, Mato JM and Lu SC: Deregulated methionine
adenosyltransferase α1, c-Myc, and Maf proteins together promote
cholangiocarcinoma growth in mice and humans (double dagger).
Hepatology. 64:439–455. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao S, Wang J and Qin C: Blockade of
CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma
progression and metastasis via inactivation of canonical Wnt
pathway. J Exp Clin Cancer Res. 33:1032014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee SJ, Kim JE, Kim ST, Lee J, Park SH,
Park JO, Kang WK, Park YS and Lim HY: The correlation between serum
Chemokines and clinical outcome in patients with advanced biliary
tract cancer. Transl Oncol. 11:353–357. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li L, Lei QS, Zhang SJ, Kong LN and Qin B:
Screening and identification of key biomarkers in hepatocellular
carcinoma: Evidence from bioinformatic analysis. Oncol Rep.
38:2607–2618. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
DeMorrow S, Onori P, Venter J, Invernizzi
P, Frampton G, White M, Franchitto A, Kopriva S, Bernuzzi F,
Francis H, et al: Neuropeptide Y inhibits cholangiocarcinoma cell
growth and invasion. Am J Physiol Cell Physiol. 300:C1078–C1089.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
DeMorrow S, Onori P, Venter J,
Leyva-Illades D, Francis H, Frampton G, Pae HY, Quinn M, Onori P,
Glaser S, et al: Neuropeptide Y inhibits biliary hyperplasia of
cholestatic rats by paracrine and autocrine mechanisms. Am J
Physiol Gastrointest Liver Physiol. 305:G250–G257. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu CH, Huang Q, Jin ZY, Zhu CL, Liu Z and
Wang C: miR-21 and KLF4 jointly augment epithelial-mesenchymal
transition via the Akt/ERK1/2 pathway. Int J Oncol. 50:1109–1115.
2017. View Article : Google Scholar : PubMed/NCBI
|
